II CANCER CELL SIGNALING PATHWAYS CONFERENCE

AN IN DEPTH LOOK AT LUNG, MELANOMA, GLIOBLASTOMA, BREAST, HEAD & NECK SQUAMOUS CELL CANCERS

Institut Germans Trias i Pujol (IGTP), Conference Meeting Room, Badalona, Barcelona, Spain - July 6th, 2017

Organized by: Rafael Rosell, Imane Chaib, Maria Gonzalez-Cao and Niki Karachaliou

Graphical Abstract

Highlights:

Co-activation of receptor tyrosine kinases and non-receptor tyrosine kinases is a common feature in cancer. Cross-talk between different signaling pathways is the basis for poly- therapy in several tumors. Rewiring of cell signals occurs as a response to therapy.

PROGRAM

08:30: Welcome

8:45 – 9:00: Cell maps for gauging the evolution of cancer - Rafael Rosell, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain

SESSION I Chairpersons: Miguel Angel Molina and Niki Karachaliou

9:00 – 9:30: Signal transducer and activator of transcription 3 (STAT3) and YES-associated protein 1 (YAP1) signaling in EGFR mutant non-small-cell lung cancer limits targeted therapy response

Targeted pathway inhibitors (western blots and in vitro viability assays) - Imane Chaib, Cancer Biology & Precision Medicine Program , Germans Trias i Pujol Health Sciences Institute, Badalona, Spain

Mouse models and quantitative RT- PCR in EGFR mutant NSCLC patients - Niki Karachaliou, IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain

9:30 - 9:45: Discussion

9:45 – 10:15: The missing view in cancer biology and the contribution of patients’ families − Lars Soraas, Oslo, Norway − Jo Monsen, Oslo, Norway

10:15 – 10:30: The view of the clinical investigator − Nuno Gil, Champalimaud Cancer Center, Lisbon, Portugal

10:30 – 10:45: Coffee Break

SESSION II Chairpersons: Niki Karachaliou and Miguel Angel Molina

10:45 – 12:15: Co-activation of receptor tyrosine and non-receptor tyrosine kinases in EGFR mutant NSCLC

Phospho-receptor kinase antibody arrays and immunofluorescence - Jordi Berenguer, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain

Quantitative RT-PCR and colony formation assays - Jill Bracht, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain

In vitro viability assays to audit TPX-0005, cabozantinib, dasatinib and HP90i - Imane Chaib, Cancer Biology & Precision Medicine Program , Germans Trias i Pujol Health Sciences Institute, Badalona, Spain - Jordi Codony, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain - Jill Bracht, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain

Concomitant or alternate treatment with EGFR TKIs - Jordi Berenguer, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain

Differential sensitivity with gefitinib, osimertinib, afatinib and dacomitinib - Marta Horcas, Cancer Biology & Precision Medicine Program , Germans Trias i Pujol Health Sciences Institute, Badalona, Spain

Mouse models - Niki Karachaliou, IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain

Phase I clinical trial with osimertinib (or other EGFR TKIs) plus TPX-0005 in first line EGFR mutant NSCLC - Niki Karachaliou, IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain

12:15 – 12:30: Discussion

SESSION III Chairpersons: Imane Chaib, Jose Luis Ramirez

12:30 – 12:45: Squamous cell carcinoma of the lung - Alberto Verlicchi, SC Oncologia. Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

12:45 – 13:15: Squamous cell carcinoma of head and neck - Rafael Rosell, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain

13:15 – 13:30: RESPONSE project: Exploiting chromatin for drug response - Marcus Buschbeck, Josep Carreras Leukaemia Research Institute, Germans Trias i Pujol Health Sciences Institute, Badalona, Spain

13:30 – 13:45: Relevance of PTPRT mutations and STAT3 signaling - Jose Luis Ramirez, Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain

13:45 – 14:00: Discussion and Lunch

SESSION IV Chairpersons: Carles Codony, Maria de los Llanos Gil

14:00 – 14:15: KRAS mutant NSCLC

Tracking signaling pathways - Chiara Lazzari, Dept. of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, Milan, Italy

In vitro viability assays to audit different targeted combinations - Carles Codony, Coyote Research Group, Pangaea Oncology, Quirón-Dexeus Hospital, Barcelona, Spain

14:15 – 14:30: Discussion

SESSION V Chairpersons: Luis Montuenga, Santiago Ramon y Cajal

14:30 – 14:45: New insights in MNKs − Santiago Ramón y Cajal, Pathology Dept. Vall d’ Hebron University Hospital, Barcelona, Spain

14:45 – 15:00: The relevance of paracrine cross-talk in lung carcinogenesis − Luis M. Montuenga, Center for Applied Medical Research, CIMA, Pamplona, Spain

15:00 – 15:15: Discussion

15:15 – 15:30: Interferon gamma signaling pathway and response to immune checkpoint inhibitors in NSCLC and melanoma - Maria Gonzalez Cao, IOR, Quiron-Dexeus Hospital, Barcelona, Spain

15:30 – 15:45: Intratumor heterogeneity in small-cell-lung cancer and NOTCH signaling - Niki Karachaliou, IOR, Hospital Sagrat Cor and Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain

SESSION VI Chairpersons: Andres Felipe Cardona, Miguel Angel Molina

15:45 – 16:00: AXL in triple negative breast cancer - Libero Santarpia, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain

16:00 – 16:15: Discussion

16:15 – 16:30: EGFR mutations in early resected NSCLC - Masaoki Ito, Coyote Research Group, Pangaea Oncology, Quiron-Dexeus Hospital, Barcelona, Spain - 16:30 – 16:45: EGFR mutations in Latin America

- Andres Felipe Cardona, Clinica del Country, Bogota, Colombia

16:45 – 17:00: Discussion/Coffee break

SESSION VII Chairpersons: Bartomeu Massuti, Santiago Viteri

17:00 – 17:15: SLCG clinical trials - Bartomeu Massuti, Hospital General de Alicante, Spain

17:15 – 17:30: Improving clinical trials - Alejandro Martinez Bueno, IOR, Quiron-Dexeus Hospital, Barcelona, Spain

17:30 – 17:45: Moving forward with clinical trials - François Riva, MedSir, Barcelona, Spain

17:45 – 18:00: Immune checkpoint inhibitor therapy in HIV positive cancer patients - Maria Gonzalez Cao, IOR, Quiron-Dexeus Hospital, Barcelona, Spain

18:00 – 18:30: Round Table:

Views on amalgamating research for improving cancer care - Chairs: Bartomeu Massuti and Santiago Viteri - Nuno Gil, Lars Soraas, Jo Monsen, François Riva, Alejandro Martinez Bueno, Niki Karachaliou, Maria Gonzalez Cao, Andres Felipe Cardona, Masaoki Ito

18:30: CLOSING REMARKS

Cancer Biology and Precision Medicine Laboratory

Supporting companies

For free registration, click on the link below :

For more general information, here is the meeting web::

How to get to the IGTP/IMPPC

By car / taxi: We are 20 minutes from the center of the city and the most convenient way to arrive is by car or taxi. We are close to the Hospital which can serve as a good point of reference:

Hospital Universitari Germans Trias I Pujol (Popularly known as Can Rutí) GPS: 41°29’06.66”N 2°14’21.27”E

From Barcelona take B20 (Rondas and Nus de la Trinitat) in direction Mataró. The hospital is well signed from the exit 21 (Badalona Centre) of the B20.

With the collaboration of Harvey Evans, Lourdes Franquet and Stephanie Davis